Left ventricular hypertrophy (LVH) is often encountered cardiac disorder with heterogeneous
clinical presentation and course. Although unexplained LVH is the hallmark of hypertrophic
cardiomyopathy, differential diagnosis of secondary cardiomyopathies with LVH has
been needed. Because, disease-oriented treatments have made progress. For example,
the enzyme replacement therapy for Anderson-Fabry disease promises the modification
of natural course of disease. In the first half of this presentation, we will overview
the clinical significance of diagnostic procedures such as medical history, physical
examination, laboratory data, electrocardiography, echocardiography, cardiac magnetic
resonance, and cardiac catheterization including endomyocardial biopsy, in secondary
cardiomyopathies with LVH. Particularly, we have been reported the clinical utility
of biomarkers in differential diagnosis and risk assessment in cardiomyopathies with
LVH from the regional cardiomyopathy registry named Kochi Cardiomyopathy Network.
In the second half of this presentation, we will suggest the new strategy of differential
diagnosis of secondary cardiomyopathies with LVH.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Cardiac FailureAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
